Esper BioSciences, Inc.
Esper Biosciences aims to develop a low-cost, high-speed DNA sequencer, for use in point-of-care medical diagnostics and scientific research.
Esper Biosciences aims to develop a low-cost, high-speed DNA sequencer, for use in point-of-care medical diagnostics and scientific research.
VitaMe Technologies (DBA VitaScan™) has developed a smartphone based diagnostic platform enabling accurate, fast, convenient, and low cost testing of vitamins and micronutrients in the home and at local pharmacies and clinics. The company received $1.15 million of grant funding from the United States Department of Defense in 2020.
Adepa Biosciences (formerly Vernx Biotechnology) is developing a range of nutrition products using branched fatty acids (BCFA) for multiple uses: to improve gastrointestinal health in pre-mature and non-premature infants, as a nutritional supplement for adults, and for eventual therapeutic use.
Computational Textiles, Inc is a small employee-owned company founded to create textile visualization and manufacturing software. The company’s first product, Weft, is a web application and manufacturing process that enables anyone to transform design ideas into intricately patterned woven cloth.
AffyImmune is an immuno-oncology company that develops T cell products for cancer therapy. The company was founded based on intellectual property generated from Weill Cornell Medicine that enables imaging of T cells in patients and T cells to specifically target tumors. The company has two products in the pipeline, and are ready to commence clinical trials in 2018
Ecolectro develops structurally robust and highly conductive polymer membranes for a range of applications, including electrolysis and fuel cell systems that not only improve performance but also dramatically decrease costs.
CycloPure is engaged in the design, development, and commercialization of a new class of highly adsorbent materials for use in the separation and removal of pollutants, VOCs, and other organic compounds from water and air. The technology was partly developed by the Helbling Research Group at The School of Civil and Environmental Engineering. CycloPure has raised $8.81M in funding to date.
Annapurna Therapeutics is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases. Annapurna’s product pipeline includes programs for alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), the cardiomyopathy associated with Friedreich’s ataxia and severe allergy. Annapurna Therapeutics was acquired by Avalanche Biotechnologies, Inc. in 2016.
XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.
Conamix is commercializing high performance battery materials based on proprietary Cornell technology. The company’s unique battery materials allow higher energy density in existing lithium ion architectures and are manufactured using low cost and highly commercial methods.